VANLENT ANNE 4
4 · Trevi Therapeutics, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
VANLENT ANNE
Director
Transactions
- Conversion
Common Stock
2019-05-09+20,983→ 20,983 total - Conversion
Series C Preferred Stock
2019-05-09−47,807→ 0 total→ Common Stock (5,582 underlying) - Purchase
Common Stock
2019-05-09$10.00/sh+5,000$50,000→ 25,983 total - Conversion
Series A Preferred Stock
2019-05-09−107,977→ 0 total→ Common Stock (15,401 underlying)
Footnotes (2)
- [F1]On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.